Clinical Phase Biotech, 15% Conv. Notes, 20% Disc.

Accredited Investors Only. Pre-IPO stage. 2021-2023 audited, 2024 audit is in progress. Offering annual 15% interest notes maturing in 2 years or convertible into common shares at a 20% discount (i) within 30 days after effectuation by the SEC, or (ii) redeemable at 1.5x face value, at the holder's option.

Business conceives and incubates pharmaceutical innovations focused on the roles the atoms of zinc, iron, magnesium, and other metals play in cellular functions throughout the body. Through its subsidiaries, the company advances a vast pipeline of proprietary isotopically modified compounds via three principal verticals: monotherapies, combination therapies, and drug analogs. Drug candidates include isotope-selective modulators of the primary metabolic, signal transduction, and gene regulation pathways with downstream therapeutic effects through GLS, NF-kB, PARP1, TNF-α, p53, and other pathways. Therapeutic benefits span over oncology, neurology, hepatology, endocrinology, hematology, cardiology, and virology areas. The company has its first lead candidate, small molecule KLS-1, in the clinical phase and over 20 new molecules in preclinical development. The company is headquartered in Miami, Florida, and operates internationally.